FDA perspective: Enrolment of elderly transplant recipients in clinical trials

Transplantation

Volumn 95, Issue 7, 2013, Pages 916-918

  Meyer, Joette M ^a   Archdeacon, Patrick ^a   Albrecht, Renata ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical trials; Efficacy; Elderly; FDA; Safety

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DRUG RESEARCH; ELDERLY CARE; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL STATUS; GERIATRIC PATIENT; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER FAILURE; LIVING DONOR; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; RESEARCH SUBJECT; REVIEW; UNITED STATES;

AGE FACTORS; AGED; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PATIENT SAFETY; PATIENT SELECTION; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876289552     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31828279d9     Document Type: Review

References (20)

1. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783.
2. Talarico L, Chen G, Padzur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626.
3. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011; 171: 550.
4. Blosser CD, Huverserian A, Bloom RD, et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation 2011; 91: 858.
5. Guideline for the Study of Drugs Likely to Be Used in the Elderly. November 1989. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072048.pdf.
6. Guideline for IndustryVStudies in Support of Special Populations: Geriatrics (ICH E7). August 1994. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM073131.pdf.
7. Draft Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal FunctionVStudy Design, Data Analysis, and Impact on Dosing and Labeling. March 2010. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM204959.pdf.
8. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic FunctionVStudy Design, Data Analysis, and Impact on Dosing and Labeling. May 2003. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
9. Guidance for Industry: Drug Metabolism/Drug Interactions Studies in the Drug Development Process: Studies In Vitro. April 1997. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072104.pdf.
10. Guidance for Industry: InVivo Metabolism/Drug Interactions StudiesV Study Design, Data Analysis, and Recommendations for Dosing and Labeling. November 1999. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf.
11. Report to Congress. Reports on Postmarketing Studies [FDAMA 130]. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/ document/ucm071529.pdf.
12. Specific requirements on content and format of labeling for human prescription drugs; addition of ''geriatric use'' subsection in the labeling. 62 Federal Register 45313, August 27, 1997. http://www.gpo.gov/fdsys/granule/FR- 1997-08-27/97-22701/content-detail.html.
13. Guidance for Industry: Content and Format for Geriatric Labeling. October 2001. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm075062.pdf.
14. Vincenti F, Charpentier B, Vanrenterghem Y, et al A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
15. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010; 10: 547.
16. NULOJIX\ (belatacept). Prescribing information. June 2011. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125288s0000lbl.pdf.
17. Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? Drugs Aging 2001; 18: 751.
18. Martins PN, Pratschke J, Pascher A, et al. Age and immune response in organ transplantation. Transplantation 2005;79:127.
19. Huang E, Segev DL, Rabb H. Kidney transplantation in the elderly. Semin Nephrol 2009; 29: 621.
20. Foreign Data. 21 Code of Federal Regulations 314.106. http://www.gpo. gov/fdsys/pkg/CFR-2006-title21-vol5/pdf/CFR-2006-title21-vol5-sec314-106.pdf.